Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

Tandem Diabetes Care, Inc.’s TNDM impressive product launches are expected to bolster growth in the upcoming quarters. A strong solvency looks encouraging. However, concerns loom over fierce ...

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering gross margin profile is poised to witness an inflection point this year. As you ...

DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day ...

New data show that wearable neuromodulation can be used with CGMs without disrupting glucose accuracy or connectivity.

In episode six of the Xpeng G6 ownership series, we compare the original model with the updated facelift version shown at an Xpeng Experience Day. We look at exterior changes such as the new ...

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.